Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Committee reviews H.209 to add intranasal epinephrine to school stock
Summary
House Education heard testimony on H.209, a bill to add intranasal epinephrine to the current authorization for stock epinephrine in Vermont schools; nurses urged clarifying language on who may delegate administration and how protocols are written.
The House Committee on Education on Feb. 27, 2025, heard testimony on H.209, an act to authorize intranasal epinephrine as part of school stock medication. Testifiers including school nurses said intranasal formulations could help address shortages and reduce costs for school nursing budgets.
The proposal would add intranasal epinephrine to existing law that permits schools to maintain a stock supply of epinephrine auto-injectors. Kathleen Goodell, a school nurse in southern Vermont, told the committee that recently the district could not obtain stock auto‑injectors, forcing schools to buy replacements that cost about $500 per school and strain nursing budgets. Goodell said an intranasal product recently approved by the U.S. Food and Drug Administration is being offered through a program that provides four single‑use doses free to each public K–12 school;…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
